

Modern Slavery Act Statement For the financial year ending 31 December 2019

Intercept Pharma Europe Limited (“Intercept”) supports the UK’s Modern Slavery Act 2015 and is committed to sound corporate governance principles, practices, and policies. To learn more about our corporate compliance policies, please visit: <https://www.interceptpharma.com/corporate-compliance/>.

Managing modern slavery risks

We recognize our responsibility to identify, mitigate and address potential and actual human rights risks that are directly linked to our business activities around the world. While the potential for modern slavery and human trafficking is relatively lower in the highly regulated biopharmaceutical industry than in many other industries, we recognize that this responsibility also extends to our business relationships.

We continue to take steps to mitigate the risks associated with slavery and human trafficking in our business and supply chain. These include the below activities:

- **Verification and risk assessment:** As part of our procurement vendor diligence process, all high-risk suppliers are vetted by our screening process which is intended to flag identified modern slavery and human trafficking risks. We have implemented a centralized Vendor Management and Onboarding process and technology in order to increase Vendor information efficiency with a centralized information base, identity and manage vendor risk as well as increase monitoring of vendor performance. This process covers multiple lines of vendor due diligence including but not limited to Anti-Slavery, Anti-Corruption Anti-Bribery, Compliance, Quality Assurance, Data Privacy and Information Technology.
- **Employee training:** Our Global Code of Business Conduct outlines expectations for employees to conduct business with integrity. New and existing employees are periodically required to review the Code and complete required training. We also provide a compliance hotline where employees can report any matters of concern from a compliance or policy perspective and report anonymously if they wish.
- **We have put in place and continue to update our annual compliance process with our distributors which, amongst other matters, reinforces our joint commitment to conducting business ethically.** In addition, we launched our *Supplier & Distributor Code of Conduct* across Europe in May 2019 which sets out our high standards and expectations when it comes to business conduct, and sets out our commitment to ensuring that we only partner with suppliers and distributors sharing our vision for adopting and maintaining responsible and sustainable business practices. Our key suppliers and distributors in Europe have received this *Code of Conduct* and it is now incorporated into the terms of our standard vendor agreements used across that region.

We will report on further progress in our next statement.

This statement has been prepared pursuant to Section 54(1) of the Modern Slavery Act 2015 and outlines Intercept’s policies and efforts to mitigate the risks of slavery and human trafficking throughout our business and supply chain for the financial year ending 31 December 2019. It has been approved by the board of directors of Intercept and is signed by a director



Lisa Bright
President, International
Intercept Pharma Europe Limited

02/07/2020

Date